Value of different modalities of granulocyte-macrophage colony- stimulating factor applied during or after induction therapy of acute myeloid leukemia

Journal of Clinical Oncology

Volumn 15, Issue 12, 1997, Pages 3496-3506

  Lowenberg B ^a   Boogaerts, M A ^a   Daenen, S M G J ^a   Verhoef, G E G ^a   Hagenbeek, A ^a   Vellenga, E ^a   Ossenkoppele, G J ^a   Huijgens, P C ^a   Verdonck, L F ^a   van der Lelie, J ^a   Wielenga, J J ^a   Schouten, H C ^a   Gmur J ^a   Gratwohl, A ^a   Hess, U ^a   Fey, M F ^a   van Putten, W L J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; ANTHRACYCLINE ANTIBIOTIC AGENT; CYTARABINE; CYTOKINE; DAUNORUBICIN; ETOPOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1; MITOXANTRONE; MOLGRASTIM; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BONE MARROW RESCUE; BONE MARROW TOXICITY; BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FLUID RETENTION; HEMATOPOIESIS; HOSPITALIZATION; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; NEPHROTOXICITY; PNEUMONIA; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; REGENERATION; SEPTICEMIA; THROMBOCYTE TRANSFUSION; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0342460479     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.12.3496     Document Type: Article

References (35)

1. Yates J, Glidewell O, Wiernik PH, et al: Cytarabine with daunorubicin or Adriamycin for therapy of acute myeloid leukemia: A CALGB study. Blood 60:454-463, 1982
2. Berman E, Heller G, Santorsa J, et al: Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 77:1666-1674, 1991
3. Wiernik PH, Banks PLC, Case DC, et al: Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 79:313-319, 1992
4. Arlin Z, Case DC, Moore J, et al: Randomised multicenter trial of cytarabine with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Leukemia 4:177-183, 1990
5. Mayer RJ, Davis RB, Schiffer CA, et al: Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 331:896-903, 1994
6. Zittoun R, Mandelli F, Willemze R, et al: Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 332:217-223, 1995
7. Bishop JF, Matthews JP, Young GA, et al: A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 87:1710-1717, 1996
8. Löwenberg B: Post-remission treatment of acute myelogenous leukemia. N Engl J Med 332:260-262, 1995 (editorial)
9. Stone RM, Berg DT, George SL, et al: Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N Engl J Med 332:1671-1677, 1995
10. Dombret H, Chastang C, Fenaux P, et al: A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. N Engl J Med 332:1678-1683, 1995
11. Rowe JM, Andersen JW, Mazza JJ, et al: A randomized placebo-controlled phase III study of granulocyte-macrophage colony- stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group. Blood 86:457-462, 1995
12. Bhalla K, Birkhofer M, Arlin Z, et al: Effect of recombinant GM-CSF on the metabolism of cytosine arabinoside in normal and leukemic human bone marrow cells. Leukemia 2:810-813, 1988
13. Lista P, Porcu P, Avanzi GC, Pegocaro L: Interleukin-3 enhances the cytotoxic activity of 1-beta-D arabinofuranosylcytosine (Ara-C) on acute myeloblastic leukaemia (AML) cells. Br J Haematol 69:121, 1988 (abstr)
14. Cannistra SA, Groshek P, Griffin JD: Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia. Leukemia 3:328-334, 1989
15. Tafuri A, Andreef M: Kinetic rationale for cytokine-induced recruitment of myeloblastic leukemia followed by cycle-specific chemotherapy in vitro. Leukemia 4:826-834, 1990
16. Bhalla K, Holladay C, Arlin Z, et al: Treatment with interleukin-3 plus granulocyte-macrophage colony-stimulating factors improves the selectivity of Ara-C in vitro against acute myeloid leukemia blasts. Blood 78:2674-2679, 1991
17. Boekhorst PAW, Löwenberg B. Vlastuin M, et al: Enhanced chemosensitivity of clonogenic blasts from patients with acute myeloid leukemia by G-CSF, IL-3 or GM-CSF stimulation. Leukemia 7:1191-1198, 1993
18. Löwenberg B, Touw IP: Hematopoietic growth factors and their receptors in acute leukemia. Blood 81:281-292, 1993
19. Bennett JM, Catovsky D, Daniel MT, et al: Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 103:620-625, 1985
20. Bennett JM, Catovsky D, Daniel MT, et al: Proposal for the recognition of minimally differentiated acute myeloid leukemia (AML-MO). Br J Haematol 78:325-329, 1991
21. Mitelman F (ed): Guidelines for Cancer Cytogenetics; Supplement to An International System for Human Cytogenetic Nomenclature. Basel, Switzerland, Karger, 1991
22. Keating MJ, Smith TL, Kantarjian H, et al: Cytogenetic pattern in acute myelogenous leukemia: A major reproducible determinant of outcome. Leukemia 2:403-412, 1988
23. Schiffer CA, Lee EJ, Tomiyasu T, et al: Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. Blood 73:263-270, 1989
24. Bloomfield CD, Lawrence D, Arthur DC, et al: Curative impact of intensification with high-dose cytarabine in acute myeloid leukemia (AML) varies by cytogenetic group. Blood 84:111a, 1994 (suppl 1, abstr)
25. Cassileth PA, Lynch E, Hines JD, et al: Varying intensity of postremission therapy in acute myeloid leukemia. Blood 79:1924-1930, 1992
26. Burnett AK, Goldstone AH, Stevens R, et al: Allo and auto BMT reduce relapse risk in AML in CR1 but do not significantly improve overall survival: results of the MRC AML 10 trial. Br J Haematol 93:1184a, 1996 (abstr)
27. Ohno R, Naoe T, Kanamaru A, et al: A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Blood 83:2086-2092, 1994
28. Löwenberg B, Suciu S, Archimbaud E, et al: Use of recombinant granulocyte-macrophage colony-stimulating-factor (GM-CSF) during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: Final report of AML-11, a phase III randomized study of the EORTC-LCG and HOVON groups. Blood 1997 (in press)
29. Begley CG, Metcalf D, Nicola NA: Primary human myeloid leukemia cells: Comparative responsiveness to proliferative stimulation by GM-CSF or G-CSF and membrane expression of GSF receptors. Leukemia 1:1-8, 1987
30. Budel LM, Touw IP, Delwel R, et al: Interleukin 3 and granulocyte-monocyte colony stimulating factor receptors on human acute myelocytic leukemia cells and relationship to the proliferative response. Blood 74:565-571, 1989
31. Budel LM, Touw IP, Delwel R, et al: Granulocyte colony stimulating factor (G-CSF) receptors on human acute myelocytic leukemia. Blood 74:2668-2673, 1989
32. Park LS, Waldron PE, Friend D, et al: Interleukin-3, GM-CSF and G-CSF receptor expression on cell lines and primary leukemia cells: Receptor heterogeneity and relationship to growth factor responsiveness. Blood 74:56-65, 1989
33. + subpopulation of acute myeloid leukemia. Blood 87:2187-2194, 1996
34. Witz F, Harousseau JL, Sadoun A, et al: GM-CSF during and after remission induction treatment for elderly patients with acute myeloid leukemia (AML). Blood 86:512a, 1995 (suppl 1, abstr)
35. Zittoun R, Suciu S, Mandelli F, et al: Granulocytemacrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: A randomized trial by the European Organization for Research and Treatment of Cancer and Leukemia Cooperative Group. J Clin Oncol 14:2150-2159, 1996